#LOY-002 FDA status Articles

As of September 19, 2026, none of Loyal's dog longevity drugs is FDA-approved or commercially available. LOY-002 has completed FDA RXE and Target Animal Safety review, with manufacturing/CMC still in progress; LOY-001 has RXE acceptance; and LOY-003 received RXE acceptance on September 16, 2026. See current eligibility targets, STAY trial status, what conditional approval means, and why no final retail price or proven one-year lifespan gain exists yet.